Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

IRI Separation Technologies Inc.
Unit 202 – 30585B Progressive Way
Abbotsford, BC V2T 6W3

Item 2 Date of Material Change

August 7, 2007

Item 3 News Release

The news release was disseminated on August 9, 2007.

Item 4 Summary of Material Change

The Company announced that it closed its previously announced private placement, including an over-allotment, for a total of 9,857,143 Units at $0.35 for gross proceeds of $3,450,000; the grant of stock options and the election of a new director.

Item 5 Full Description of Material Change

See attached news release.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not Applicable

Item 7 Omitted Information

None

Item 8 Executive Officer

For more information, please contact John Mason, President & CEO, Telephone: 604-807-8694

DATED: August 10, 2007

"John Mason"

Per: John Mason
President and Chief Executive Officer

FOR IMMEDIATE RELEASE

Closing of $3.45 M Private Placement, Grant of Options and New Director

Vancouver, British Columbia – August 9, 2007 – **IRI Separation Technologies Inc.** (TSXV: IRI) (the "Company") is pleased to announce that it has closed the amended private placement that was disclosed in a news release dated July 27, 2007. The Company has issued 9,857,143 units at a price of $0.35 per unit (a "Unit"), and received gross proceeds of $3,450,000. Each Unit consists of one common share and one warrant, entitling the holder to purchase one common share for 24 months at $0.45 per share. The Company paid a 10% cash finders fee in connection with the sale of the majority of the Units.

The proceeds from the sale of the Units will be used for general working capital and to purchase additional equipment to increase antibody production. All securities are subject to a four month hold period commencing from the date of closing.

The Company also announced the grant of 1,180,000 stock options under the incentive stock option plan to certain directors, officers, employees and consultants. The options shall be exercisable at a price of $0.38 per share for a period of five years, and are subject to a vesting schedule whereby 25% of the options shall vest on dated that are 3, 6, 9 and 12 months after the date of grant.

Lastly, the Company is pleased to announce that a new director, Wayne Christensen, was elected to the board of directors of the Company at the annual general meeting held on July 27, 2007. Mr. Christensen is a successful businessman with experience in nutraceutical distribution who is also a significant shareholder of the Company.

About IRI Separation Technologies Inc.

IRI Separation Technologies Inc. (TSXV: IRI) is a biotechnology company that specializes in the extraction, development and commercialization of monoclonal and polyclonal immunoglobulin antibodies for virus and bacteria related health issues. Intended for use as a nutraceutical for human consumption, the antibodies are derived from bovine whey or chicken eggs. The immunoglobulin antibodies are intended for both the general and specific antibody market.

On behalf of the Board of Directors, John Mason, President and CEO.

For further information contact:

Vancouver Office:
John Mason, IRI Separation Technologies Inc.
Phone: 604.807.8694
Fax: 604.926.1485
Email: jmason@iriseparation.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.